PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors
Authors
Keywords
Advanced cancer, NSCLC, CTCs, PD-1, Predictive, Immune Checkpoint
Journal
Clinical Lung Cancer
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-03-19
DOI
10.1016/j.cllc.2021.03.005
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
- (2020) Francesco Facchinetti et al. EUROPEAN JOURNAL OF CANCER
- ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world data
- (2020) Filippo G. Dall’Olio et al. LUNG CANCER
- Heterogeneous expression of programmed death receptor-ligand 1 on circulating tumor cells in patients with lung cancer
- (2019) Yasuhiro Koh et al. Clinical Lung Cancer
- Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors
- (2019) Ernest Nadal et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Circulating tumor cells in patients with lung cancer: developments and applications for precision medicine
- (2019) Bing Tong et al. Future Oncology
- Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors
- (2019) Menno Tamminga et al. Journal for ImmunoTherapy of Cancer
- Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
- (2019) Melanie Janning et al. Cancers
- EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer
- (2019) C.R. Lindsay et al. EUROPEAN JOURNAL OF CANCER
- PD‐L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study
- (2019) Muhammad A. Khattak et al. ONCOLOGIST
- PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab
- (2018) Nicolas Guibert et al. LUNG CANCER
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy
- (2018) Chunyan Yue et al. OncoImmunology
- Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer
- (2018) Laura Mezquita et al. JAMA Oncology
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer
- (2018) Vincenzo Di Nunno et al. Frontiers in Oncology
- The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer
- (2018) Arutha Kulasinghe et al. Cancer Medicine
- The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
- (2018) Massimo Cristofanilli et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability
- (2017) Enrico Munari et al. Oncotarget
- Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
- (2017) Paul C. Tumeh et al. Cancer Immunology Research
- Circulating Tumor Cells: A Review of Non-EpCAM-Based Approaches for Cell Enrichment and Isolation
- (2016) M. T. Gabriel et al. CLINICAL CHEMISTRY
- Circulating Tumor Cells Detected in the Tumor-Draining Pulmonary Vein Are Associated with Disease Recurrence after Surgical Resection of NSCLC
- (2016) Phil A.J. Crosbie et al. Journal of Thoracic Oncology
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating Tumor Cells Identify Early Recurrence in Patients with Non-Small Cell Lung Cancer Undergoing Radical Resection
- (2016) Clara Bayarri-Lara et al. PLoS One
- Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
- (2016) Joseph McLaughlin et al. JAMA Oncology
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Relationship between circulating tumour cell count and prognosis following chemotherapy in patients with advanced non-small-cell lung cancer
- (2015) Zixuan Zhang et al. RESPIROLOGY
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- The detection of EpCAM+ and EpCAM– circulating tumor cells
- (2015) Sanne de Wit et al. Scientific Reports
- Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research
- (2014) P. K. Grover et al. ANNALS OF ONCOLOGY
- Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches
- (2011) Matthew G. Krebs et al. Journal of Thoracic Oncology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now